Aquestive Therapeutics (AQST)
Develops PharmFilm oral medicines and manufactures licensed films for global partners.
Something off on this page? Send us feedback.
Develops oral-film medicines through PharmFilm, with commercial revenue from licensed manufacturing, royalties, and collaborations. The proprietary pipeline is centered on Anaphylm for severe allergic reactions and Libervant for seizure clusters, both shaped by FDA review, litigation, and market-access constraints.
Built around PharmFilm, a proprietary oral-film delivery technology used in buccal, sublingual, and lingual formats. Commercial activity comes from manufacturing licensed products such as Suboxone, Sympazan, Ondif, and Emylif, while proprietary development focuses on rescue medicines including Anaphylm and Libervant.
Operations are U.S.-based, with headquarters and research in Warren, New Jersey and manufacturing in Portage, Indiana. The model depends on film formulation know-how, controlled manufacturing, licensee relationships, and regulatory execution.
Anaphylm remains unapproved after an FDA complete response tied to human-factors validation and a packaging-related pharmacokinetic study. Libervant's U.S. access remains constrained by orphan-exclusivity litigation and tentative approval timing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | Cantor Fitzgerald | Reiterate | Rating: —Target: — | Target: $11 |
| Feb 3, 2026 | Lake Street | Target | Target: — | Target: $6 |
| Feb 2, 2026 | New Street | Target | Target: — | Target: $12 |
| Oct 9, 2025 | JMP Securities | Reiterate | Rating: —Target: — | Target: $12 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $98.5M · Total debt $59.0M · Total assets $132.1M · Shareholders' equity −$56.6M
- Revenue
- $13.8M
- Operating income
- −$8.2M
- Net income
- −$22.9M
No dividends on record.
Unavailable right now.
- ARS Pharmaceuticals
Needle-free epinephrine nasal spray benchmark for oral-film rescue
- Viatris
EpiPen incumbent with a large branded auto-injector footprint
- Teva (ADR)
Generic EpiPen equivalent with broad U.S. generic-pharma reach
- Amneal Pharmaceuticals
Authorized-generic Adrenaclick auto-injector and epinephrine supplier
- Bausch Health
Diastat rectal diazepam incumbent for seizure-cluster rescue
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics | $4.94 | +3.24% | $599.7M | — | — | 11.1 | +38.2% |
| ARS Pharmaceuticals | $4.50 | +3.45% | $432.0M | — | — | 3.7 | +114.2% |
| Viatris | $17.09 | −0.06% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| Teva (ADR) | $39.83 | −0.57% | $46.66B | 66.8 | 14.2 | 2.7 | −0.8% |
| Amneal Pharmaceuticals | $19.53 | −3.11% | $6.44B | 41.4 | 19.6 | 2.1 | +9.9% |
| Bausch Health | $5.71 | +1.15% | $2.11B | — | 1.3 | 0.2 | +11.2% |
| Median | 54.1 | 10.4 | 2.1 | +9.9% |